Travere Therapeutics, Inc. (TVTX) Stock Price & Analysis
Travere Therapeutics, Inc. (TVTX) closed at USD 52.43 on Thursday, October 22, 2026, down 0.29% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 52.58; the Oct 22, 2026 session ranged USD 51.25–53.12 on volume of 1,774,173 shares. Market capitalization is $4.94B, with a 52-week range of USD 22.59–68.73 (NGM). Source: Nexqual, retrieved October 23, 2026 at 09:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/TVTX.md
Key facts (TVTX)
- Last four reported quarters (through Jun 30, 2026): revenue $591M, net income -$43.5M (-7.4% margin) (SEC filings).
- 1 of 80 tracked superinvestors hold TVTX (13F, Q2 2026): 1 new, 0 added, 0 reduced, 0 unchanged.
- Total return with dividends: 1Y +86.3% vs S&P 500 +14.9%; 5Y +99.5% vs S&P 500 +80.3%.
- Next earnings: 2026-10-29, EPS estimate USD 0.49, revenue estimate $198M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (TVTX)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $132M | $109M | $145M | $233M | $491M | $591M |
| Gross profit | $128M | $105M | $134M | $225M | $480M | — |
| Operating income | -$199M | -$320M | -$388M | -$324M | -$62.8M | -$40.5M |
| Net income | -$180M | -$278M | -$111M | -$322M | -$25.5M | -$43.5M |
| EPS (diluted) | -$3.01 | -$4.37 | -$1.50 | -$4.08 | -$0.29 | — |
| Free cash flow | -$19.9M | -$186M | -$281M | — | — | — |
| Gross margin | 97.1% | 96.0% | 92.1% | 96.7% | 97.9% | — |
| Operating margin | -151.3% | -292.2% | -267.2% | -138.9% | -12.8% | -6.8% |
| Net margin | -136.6% | -254.4% | -76.7% | -137.9% | -5.2% | -7.4% |
| Revenue growth | -33.5% | -17.0% | +32.7% | +60.5% | +110.5% | — |
| Cash + short-term investments | $428M | $347M | $307M | — | $238M | — |
| Total debt | $227M | $376M | $377M | $310M | $312M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (TVTX)
Superinvestors (SEC 13F-HR, Q2 2026) (TVTX)
1 of 80 tracked investors hold TVTX. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Polen Capital | Polen Capital Management | 0.02% | $1.9M | New position |
Analysts (TVTX)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-24 | Guggenheim | Target raised | Buy | $75 → $89 |
| 2026-09-22 | Wedbush | Reiterated | Outperform | $76 |
| 2026-09-22 | HC Wainwright & Co. | Reiterated | Buy | $67 |
| 2026-08-10 | Evercore ISI Group | Target raised | Outperform | $68 → $78 |
| 2026-08-06 | Canaccord Genuity | Target raised | Buy | $62 → $70 |
| 2026-08-06 | Wedbush | Target raised | Outperform | $61 → $75 |
| 2026-08-05 | TD Cowen | Target raised | Buy | $60 → $75 |
| 2026-08-05 | Citigroup | Target raised | Buy | $70 → $85 |
| 2026-08-05 | Evercore ISI Group | Target raised | Outperform | $60 → $68 |
| 2026-08-05 | Guggenheim | Target raised | Buy | $65 → $75 |
| 2026-07-30 | Canaccord Genuity | Target raised | Buy | $56 → $62 |
| 2026-06-25 | Guggenheim | Target raised | Buy | $56 → $65 |
Total return (dividends reinvested) (TVTX)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +86.3% | +99.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +86.7% | +14.8% |
| Volatility (annualized) | 61.9% | 65.2% |
| Max drawdown | -33.5% (Dec 2025→Mar 2026) | -83.1% (Dec 2021→Apr 2024) |
TVTX revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Total net product sales | $161.4M | 95.1% | +70.1% |
| — FILSPARI (part of Total net product sales) | $141.1M | 83.2% | +96.2% |
| — Tiopronin products (part of Total net product sales) | $20.3M | 12.0% | -11.7% |
| License and collaboration revenue | $8.2M | 4.9% | -58.0% |
| Total revenue | $169.6M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
TVTX suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | LIGAND PHARMACEUTICALS INC (LGND) | “In 2012, we entered into a license agreement with Ligand Pharmaceuticals, Inc. ("Ligand"), granting us a worldwide sublicense for the development, manufacture and commercialization of FILSPARI (sparsentan).” |
| Partner | CSL | “In April 2024, we and our partner CSL Vifor announced that the European Commission had granted conditional marketing authorization ("CMA") for FILSPARI (sparsentan) for the treatment of adults with primary IgAN with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ("UPCR") ≥0.75 g/g), and in April 2025, we and CSL Vifor announced that the European Commission had converted the CMA into a s…” |
| Partner | Renalys Pharma | “In January 2024, we announced our entry into an exclusive licensing agreement with Renalys Pharma, Inc. ("Renalys"), to bring sparsentan for the treatment of IgAN to patients in Japan and other countries in Asia.” |
Quoted from the company's 10-K filed Feb 19, 2026.
Companies that name TVTX in their SEC reports
| Relationship to TVTX | Company | Filing | Sentence |
|---|---|---|---|
| partner | Mirum Pharmaceuticals, Inc. (MIRM) | 10-K Feb 25, 2026 | “Asset Purchase Agreement with Travere Therapeutics, Inc.” |
TVTX company outlook (results filed Aug 4, 2026)
- “Topline data expected in 2H 2027 In-licensing of civorebrutinib expands long-term growth opportunities in multiple immune-mediated rare kidney diseases SAN DIEGO, August 4, 2026 – Travere Therapeutics, Inc.”
- “Program Updates FILSPARI ® (sparsentan) – IgA Nephropathy (IgAN) • The SPARX Study evaluating FILSPARI in post-transplant patients with recurrent IgAN or FSGS has completed enrollment, with data presentations anticipated in 2027. • In May 2026, the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S.”
- “Upon issuance, the patent is expected to provide U.S. patent coverage for certain methods of using sparsentan in IgA nephropathy into October 2037. • In June 2026, the Company's partner, Chugai Pharmaceutical, submitted a New Drug Application for sparsentan in Japan.”
- “Pegtibatinase (TVT-058) – Classical Homocystinuria (HCU) • The Company is continuing to enroll new patients in the pivotal Phase 3 HARMONY Study, with topline data anticipated in 2H 2027. • The HARMONY Study is expected to enroll approximately 70 patients aged 12 to 65 with plasma total homocysteine (tHcy) levels ≥50 µM.”
Quoted word-for-word from the SEC 8-K results press release.
TVTX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.49 | $0.40 | +24.2% | $198.3M | 8 |
| Next quarter (ends Dec 2026) | $1.07 | $0.85 | +26.8% | $234.4M | 8 |
| Current fiscal year (ends Dec 2026) | $1.67 | $1.88 | -11.2% | $729.5M | 8 |
| Next fiscal year (ends Dec 2027) | $5.70 | $4.77 | +19.5% | $1.09B | 8 |
Key Statistics (as of October 23, 2026 at 09:22 UTC)
| Price | USD 52.43 |
|---|---|
| Change | ▼ 0.29% (down) |
| Previous Close | USD 52.58 |
| Open | USD 52.34 |
| Day Range | USD 51.25 – 53.12 |
| 52-Week Range | USD 22.59 – 68.73 |
| Volume | 1,774,173 shares |
| Market Cap | $4.94B |
| Exchange | NGM |
Technical Analysis (TVTX)
Nexqual's technical model rates TVTX "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:22 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 36.96 (neutral) |
| vs SMA50 | Below (USD 60.63) |
| MACD | -2.6 (negative) |
Earnings (TVTX)
| Next Earnings Date | 2026-10-29 |
|---|---|
| EPS Estimate | USD 0.49 |
| Revenue Estimate | $198.32M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.1 vs est 0.32 ▼ miss |
| 2026-03-31 | USD 0.05 vs est -0.06 ▲ beat |
| 2025-12-31 | USD 0.37 vs est 0.37 ▼ miss |
| 2025-09-30 | USD 0.59 vs est -0.09 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:22 UTC.
Financials & Fundamentals (TVTX)
| Total Revenue | $591.33M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +48.20% |
| Gross Margin | +59.21% |
| Operating Margin | +2.33% |
| Profit Margin | -7.35% |
| ROE | -236.36% |
| Debt / Equity | 25.16 |
| Current Ratio | 4.05 |
| Total Cash | $489.18M |
| Total Debt | $616.91M |
Source: Nexqual, October 23, 2026 at 09:22 UTC.
Ownership (TVTX)
| Insider Ownership | +0.69% |
|---|---|
| Institutional Ownership | +116.02% |
| Shares Outstanding | 94.26M |
| Float | 93.22M |
| Short % of Float | +17.48% |
Source: Nexqual, October 23, 2026 at 09:22 UTC.
From Travere Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Idorsia Pharmaceuticals' aprocitentan (branded as Tryvio in the United States and Jeraygo in Europe) was approved for the treatment of resistant hypertension by the FDA and the European Medicines Agency in March 2024 and June 2024, respectively; the pivotal study enrolled patients with resistant hypertension, including those with Stage 3 and Stage 4 CKD.
- Our approach centers on advancing our innovative pipeline with multiple late-stage clinical programs targeting rare diseases with significant unmet medical needs.
- Our approach may vary depending on the product and will be based on a number of factors including capital necessary to execute on each option, size of the market and terms of potential collaboration and/or licensing offers from other pharmaceutical and biotechnology companies with respect to jurisdictions outside the United States. •Develop a sustainable pipeline by employing disciplined decision criteria in the evaluation of potential in-licensing candidates.
- We believe this strategy minimizes our clinical development risk and allows us to accelerate the development and potential commercialization of current and future therapeutic candidates.
Partnerships
- In 2014, we entered into a license agreement with Mission Pharmacal ("Mission"), pursuant to which we obtained an exclusive, royalty-bearing license to market, sell and commercialize Thiola (tiopronin) in the United States and Canada, and a non-exclusive license to use know-how relating to Thiola to the extent necessary to market Thiola ("Mission License Agreement").
- Orphan Technologies obtained the rights to the first five patent families under an exclusive license agreement with the University of Colorado, while the sixth patent family was owned by Orphan Technologies.
Legal & Regulatory Risks (Item 1A, quoted)
- Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval or commercialization.
- Any therapies we develop may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, thereby harming our business.
- We may not have sufficient insurance to cover our liability in any current or future litigation claims either due to coverage limits or as a result of insurance carriers seeking to deny coverage of such claims.
- Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BLTE | Belite Bio, Inc | USD 150.27 | ▼ 1.9% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| TGTX | TG Therapeutics, Inc. | USD 53.16 | ▼ 0.08% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt